155 related articles for article (PubMed ID: 38467490)
21. Comparative Behavioral Pharmacology of Three Pyrrolidine-Containing Synthetic Cathinone Derivatives.
Gatch MB; Dolan SB; Forster MJ
J Pharmacol Exp Ther; 2015 Aug; 354(2):103-10. PubMed ID: 25998047
[TBL] [Abstract][Full Text] [Related]
22. Behavioral pharmacology of designer cathinones: a review of the preclinical literature.
Gregg RA; Rawls SM
Life Sci; 2014 Feb; 97(1):27-30. PubMed ID: 24231450
[TBL] [Abstract][Full Text] [Related]
23. Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) in rhesus monkeys.
Collins GT; Sulima A; Rice KC; France CP
Psychopharmacology (Berl); 2019 Dec; 236(12):3677-3685. PubMed ID: 31346629
[TBL] [Abstract][Full Text] [Related]
24. Crystallographic investigations of select cathinones: emerging illicit street drugs known as `bath salts'.
Wood MR; Lalancette RA; Bernal I
Acta Crystallogr C Struct Chem; 2015 Jan; 71(Pt 1):32-8. PubMed ID: 25567572
[TBL] [Abstract][Full Text] [Related]
25. Synthetic Cathinone Analogues Structurally Related to the Central Stimulant Methylphenidate as Dopamine Reuptake Inhibitors.
Yadav-Samudrala BJ; Eltit JM; Glennon RA
ACS Chem Neurosci; 2019 Sep; 10(9):4043-4050. PubMed ID: 31369229
[TBL] [Abstract][Full Text] [Related]
26. α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and high and low affinity monoamine transporters.
Maier J; Rauter L; Rudin D; Niello M; Holy M; Schmid D; Wilson J; Blough BE; Gannon BM; Murnane KS; Sitte HH
Neuropharmacology; 2021 Jun; 190():108570. PubMed ID: 33864800
[TBL] [Abstract][Full Text] [Related]
27. Designer psychostimulants: pharmacology and differences.
Iversen L; White M; Treble R
Neuropharmacology; 2014 Dec; 87():59-65. PubMed ID: 24456744
[TBL] [Abstract][Full Text] [Related]
28. Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells.
Simmler LD; Liechti ME
Curr Top Behav Neurosci; 2017; 32():49-72. PubMed ID: 27272068
[TBL] [Abstract][Full Text] [Related]
29. 3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.
Magee CP; German CL; Siripathane YH; Curtis PS; Anderson DJ; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2020 Aug; 374(2):273-282. PubMed ID: 32385092
[TBL] [Abstract][Full Text] [Related]
30. Neuropharmacology of Synthetic Cathinones.
Baumann MH; Walters HM; Niello M; Sitte HH
Handb Exp Pharmacol; 2018; 252():113-142. PubMed ID: 30406443
[TBL] [Abstract][Full Text] [Related]
31. DARK Classics in Chemical Neuroscience: α-Pyrrolidinovalerophenone ("Flakka").
Kolesnikova TO; Khatsko SL; Demin KA; Shevyrin VA; Kalueff AV
ACS Chem Neurosci; 2019 Jan; 10(1):168-174. PubMed ID: 30384587
[TBL] [Abstract][Full Text] [Related]
32. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter.
Cameron K; Kolanos R; Vekariya R; De Felice L; Glennon RA
Psychopharmacology (Berl); 2013 Jun; 227(3):493-9. PubMed ID: 23371489
[TBL] [Abstract][Full Text] [Related]
33. Hazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays.
Zwartsen A; Olijhoek ME; Westerink RHS; Hondebrink L
Front Neurosci; 2020; 14():9. PubMed ID: 32063828
[TBL] [Abstract][Full Text] [Related]
34. Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats.
Naylor JE; Freeman KB; Blough BE; Woolverton WL; Huskinson SL
Drug Alcohol Depend; 2015 Apr; 149():280-4. PubMed ID: 25707704
[TBL] [Abstract][Full Text] [Related]
35. Self-administration and behavioral economics of second-generation synthetic cathinones in male rats.
Huskinson SL; Naylor JE; Townsend EA; Rowlett JK; Blough BE; Freeman KB
Psychopharmacology (Berl); 2017 Feb; 234(4):589-598. PubMed ID: 27896377
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones.
Fitzgerald LR; Gannon BM; Walther D; Landavazo A; Hiranita T; Blough BE; Baumann MH; Fantegrossi WE
Neuropharmacology; 2024 Mar; 245():109827. PubMed ID: 38154512
[TBL] [Abstract][Full Text] [Related]
37. Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in Rats.
Chojnacki MR; Thorndike EB; Partilla JS; Rice KC; Schindler CW; Baumann MH
J Pharmacol Exp Ther; 2023 Jun; 385(3):162-170. PubMed ID: 36669877
[TBL] [Abstract][Full Text] [Related]
38. The synthetic cathinone α-pyrrolidinovalerophenone (α-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects.
Nóbrega L; Dinis-Oliveira RJ
Drug Metab Rev; 2018 May; 50(2):125-139. PubMed ID: 29540067
[TBL] [Abstract][Full Text] [Related]
39. Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses.
de Moura FB; Sherwood A; Prisinzano TE; Paronis CA; Bergman J; Kohut SJ
Pharmacol Biochem Behav; 2021 Mar; 202():173112. PubMed ID: 33444603
[TBL] [Abstract][Full Text] [Related]
40. A narrative review of the neuropharmacology of synthetic cathinones-Popular alternatives to classical drugs of abuse.
Kuropka P; Zawadzki M; Szpot P
Hum Psychopharmacol; 2023 May; 38(3):e2866. PubMed ID: 36866677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
